Barrington Research Maintains Outperform on Surmodics, Raises Price Target to $71
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky has maintained an 'Outperform' rating on Surmodics (NASDAQ:SRDX) and raised the price target from $69 to $71.
November 09, 2023 | 4:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Surmodics' price target has been raised from $69 to $71 by Barrington Research, which maintains an 'Outperform' rating on the stock.
The raised price target and maintained 'Outperform' rating by Barrington Research indicates a positive outlook for Surmodics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100